Method Development and Validation for The Simultaneous Estimation of Levofloxacin and Cefpodoxime Proxetil by Using RP-HPLC in Combined Tablet Dosage Form
Abstract
An isocratic, reversed phase-liquid-chromatographic method was developed for the quantitative determination of Levofloxacin and Cefpodoxime proxetil in combined-dosage form. Alliance -Waters System with Agilant Zorbax Eclipse XBD-C8, (150mm×4.6; 5µm) column with mobile phase containing water with Ortho phosphoric acid: Methanol in the ratio of (80: 20, v/v) was used. The flow rate was 0.5 ml/min, column temperature was 40°C and effluents were monitored at 270 nm. The retention times of Levofloxacin and Cefpodoxime proxetil were 3.096min and 4.559min, respectively. The correlation co-efficient for Levofloxacin and Cefpodoxime proxetil was found to be 1.0 and 1.0, respectively. The proposed method was validated with respect to linearity, accuracy, precision, specificity, and robustness. Recovery of Levofloxacin and Cefpodoxime proxetil in formulations was found to be in the range of 97-103% and 97-103% respectively confirms the non-interferences of the excipients in the formulation. Due to its simplicity, rapidness and high precision. The method was successfully applied for the estimation of Levofloxacin and Cefpodoxime proxetil in combined dosage form.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.